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Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in the majority of lung cancer.
This study aims at defining connections between STAT3 function and the malignant properties of non–small cell
lung carcinoma (NSCLC) cells. To address possible mechanisms by which STAT3 influences invasiveness, the
expression of matrix metalloproteinase-1 (MMP-1) was analyzed and correlated with the STAT3 activity status.
Studies on both surgical biopsies and on lung cancer cell lines revealed a coincidence of STAT3 activation and
strong expression of MMP-1. MMP-1 and tyrosine-phosphorylated activated STAT3 were found co-localized in
cancer tissues, most pronounced in tumor fronts, and in particular in adenocarcinomas. STAT3 activity was
constitutive, although to different degrees, in the lung cancer cell lines investigated. Three cell lines (BEN, KNS62,
and A549) were identified in which STAT3 activitation was inducible by Interleukin-6 (IL-6). In A549 cells, STAT3
activity enhanced the level of MMP-1 mRNA and stimulated transcription from the MMP-1 promoter in IL-6–
stimulated A549 cells. STAT3 specificity of this effect was confirmed by STAT3 knockdown through RNA
interference. Our results link aberrant activity of STAT3 in lung cancer cells to malignant tumor progression
through up-regulation of expression of invasiveness-associated MMPs.
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Lung cancer is the leading cause of cancer death in the world [1].
Various molecular dysregulations have been associated with lung
cancer, including overexpression or mutation of epidermal growth
factor receptors (EGFRs) and their ligands [2], activation of Src kinase
[3], elevated expression and autocrine proliferative function of
Interleukin-6 (IL-6) [4], and aberrant nuclear expression of survivin [5].
Interestingly, a common denominator of all these situations and
processes seen in lung cancer is the involvement of signal transducer
and activator of transcription 3 (STAT3). STAT3 can be activated by
tyrosine kinase growth factor receptors such as the EGFR as well as
nonreceptor tyrosine kinases such as Src and gp130 family member
cytokines such as IL-6 [6]. It is known to upregulate genes promoting
cell cycle progression and/or preventing apoptosis [7].
98 MMP-1 and STAT3 in Lung Cancer Schütz et al. Translational Oncology Vol. 8, No. 2, 2015We and others have demonstrated aberrant activity of STAT3 in
various malignant tumors of both hematopoietic and solid types [8,9].
An important role of STAT3 activity in lung cancer was suggested by
constitutive STAT3 activation in a number of lung cancer cell lines
[10] as well as in lung cancer tissue [11].
Functional connections between STAT3 activity and dysregulated
upstream signaling processes in lung cancer have been revealed. For
instance, IL-6 and its receptor were implicated in the progression of
non–small cell lung carcinoma (NSCLC) [12] and were shown to
induce enhanced STAT3 activity [13,14]. Moreover, the EGFR
activates STAT3 in lung cancer cell lines [15] and can promote tumor
survival in vivo in NSCLC by signaling through STAT3 [16]. A
specific spectrum of STAT3 target genes is overexpressed in lung
carcinomas bearing aberrantly active mutant EGFRs [15].
Malignant properties of lung tumor cells such as hyperproliferation,
dedifferentiation, and invasiveness are associated with dysregulated EGF,
ErbB2, or IL-6/IL-11 signaling [17,18], raising the question of how
STAT3 as a downstream mediator contributes to these effects.
Invasiveness was correlated in small cell lung carcinoma (SCLC) cell
lines with the expression level of the EGFR [17]. It is tempting to assume
that STAT3-mediated gene regulation is a constituent of this connection.
STAT3 elevates the expression of matrix metalloproteinases
(MMPs) in different tumor cell types and thereby enhances invasive
cell properties [19–21]. Among these is the interstitial collagenase
MMP-1, which degrades collagen types I, II, and III and is an
established determinant of invasive growth of tumor cells [22]. We
have shown before that STAT3 directly drives MMP-1 expression in
colorectal carcinoma [21]. A role of MMP-1 in lung cancer is
suggested by clinical data: Tissue inhibitor of MMP-1 is an
independent predictor of prognosis in patients with NSCLC [23].
Moreover, a polymorphism in the MMP-1 promoter enhances lung
cancer susceptibility [24].Table 1. List of Biopsies Included in This Study With Patient Clinicopathologic Parameters and
Immunohistochemical Staining Scores for Tyrosine-Phosphorylated (activated) STAT3, STAT3,
and MMP-1
No. Histology TNM Grade Sex pYSTAT3 STAT3 MMP-1
1 SCC T2, N0, M0 G2 m − − +++
2 NSCLC T1, N3, M0 G2 w ++ ++ ++
3 AC T1, N0, M0 G2 w +++ +++ +++
4 SCC T2, N1, M0 G2 m ++ ++ +++
5 LCC T1, N0, M0 G2 m + + +
6 NSCLC T2, N2, M0 G2 m + ++ ++
7* NSCLC n.d. n. d. n. d. +++ +++ +
8 AC T4, N0, M0 G2 m − + ++
9* NSCLC n.d. n. d. n. d. ++ ++ +
10 SCC T2, N1, M0 G3 m ++ +++ +
11 AC T1, N0, M0 G2 m − − ++
12* NSCLC n.d. n. d. n. d. + + ++
13 SCC T1, N1, M0 G2 m ++ +++ ++
14 SCC T4, N3, M0 G3 m +++ +++ ++
15 AC T1, N1, M0 G2 w ++ ++ +++
16 SCC T2, N1, M0 G3 w ++ +++ +
17 SCC T2, N2, M0 G3 m ++ +++ ++
18 SCC T2, N1, M0 G3 m +++ +++ +++
19 SCC T2, N0, M0 G2 m ++ ++ ++
20 NSCLC T1, N1, M0 G1 m + + ++
21 AC T1, N1, M0 G2 m + +++ ++
22 AC T2, N0, M0 G2 w − − ++
23 AC T2, N0, M0 G3 m − + +++
24 SCC T2, N0, M0 G2 m +++ +++ +++
A tripartite, graded immunoreactive score considering both staining intensities and percentage of
signal-positive cells was employed. n.d., not defined. Asterisks indicate samples originating from open
biopsies, i.e., from patients who were not treated surgically and were not included in follow-up surveys.Here, we have addressed the role of STAT3 activation in lung
carcinoma biopsies and cell lines and its spatial and functional
association with MMP-1 expression. We present evidence for the
notion that STAT3-dependent regulation of MMP-1 expression is
involved in the pathogenesis of NSCLC.
Materials and Methods
Tumor Biopsies
Tumor specimens were obtained from lung cancer patients
diagnosed with NSCLC in accordance with the local ethics
committee. Histologic diagnosis was established according to the
guidelines of the World Health Organization; 108 lung carcinoma
biopsies [53 squamous cell carcinomas (SCCs), 43 adenocarcinomas
(ACs), 6 large cell lung carcinomas (LCCs), 3 SCLCs, and 3
adenosquamous carcinomas] were obtained in the course of tumor
resections. A subset of 24 NSCLC biopsies was employed for
biochemical studies. Detailed information on the respective patients
and tumor types are given in Table 1. Biopsies were processed for
Western blot analysis as described previously [9]. The whole
collection of 108 biopsies was subjected to immunohistochemical
analysis. Tumor types LCC, SCLC, and adenosquamous carcinoma
were not included in statistical evaluation due to small sample sizes.
Cell Lines and Cell Culture
Cell lines NCI-H69 and NCI-H82 were purchased from the American
Type Culture Collection (Manassas, VA), and cell lines A549,
EPLC-272H, BEN, and LCLC-103Hwere purchased from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (Braunschweig,
Germany). Cell lines Oka C1, KNS-62, and MR56 were gifts from Dr
G.Aust, Institute of Anatomy,University of Leipzig. All cell lines except for
A549 and BEN were cultured in RPMI 1640 containing 10% fetal calf
serum (FCS), 200 mM L-glutamine, 100 mM sodium pyruvate, and
1 mg/ml gentamicin. A549 and BEN were cultured in Dulbecco's
modified Eagle's medium. Cells were grown in coated tissue culture
plasticware. For cytokine stimulation, cells were incubated with 20 ng/ml
recombinant human IL-6 (R&D Systems, Wiesbaden, Germany) for 30
minutes (Western blot analysis), 18 hours (reporter gene assay), or 24
hours (expression analysis) at 37°C.
RNA Interference and Lentiviral Transduction
Lentivirus production and subsequent transduction of cells were
carried out as described previously [25]. The following shRNA constructs
(Sigma AldrichMission TRCLibrary) were used: shRNA against STAT3
(TRCN0000071456) and control scrambled shRNA (SHC002). The
functionality of the shRNAs was validated by quantitative reverse
transcription–polymerase chain reaction (PCR) analysis. Transduced cells
were selected for puromycin resistance before further analysis.
Western Blot Analysis
Western blot analysis has been described in detail previously [21].
Blots were probed with antibodies to pYSTAT3-Tyr705 (Cell
Signaling Technology, Danvers, MA) or MMP-1 (Merck Millipore,
Billerica, MA) at 1:1000 dilution.
DNA Constructs
MMP-1 promoter/luciferase constructs were generated starting
from plasmid −4372 hMMP-luci (GenBank: AF023338), obtained
from C. E. Brinckerhoff [26]. Construction of pMMP-1-0.6 k and
mutations thereof has been described [21,26].
Figure 1. Analysis of STAT activity and MMP-1 expression in
extracts of NSCLC biopsies. (A) Examination of tumor sample
lysates for activated STAT3 by Western blot analysis. Extracts from
12 arbitrarily chosen tumor biopsies were separated by polyacryl-
amide gel electrophoresis (PAGE), subjected to Western blot, and
then probed with an antibody to tyrosine-phosphorylated STAT3
(top) and reprobed with an antibody to STAT3 (center). Arrows
indicate the positions of STAT3 isoforms. Comparable loading of
lanes was confirmed by staining with Ponceau S (bottom). (B)
Analysis of tumor samples for MMP-1 expression. Lysates from
the same NSCLC biopsies as in A were subjected to Western blot
and probed with an antibody to MMP-1. Positions of latent and
active MMP-1 are indicated by arrows.
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Immunohistologic detection of pYSTAT3 activity and MMP-1
expression in tumor biopsies and fluorescence immunolabeling were
performed as described previously [9,27,28]. Negative controls were
performed using an irrelevantmonoclonal antibody. Staining intensities
were classified employing a graded immunoreactive score (−, +, ++, and
+++) estimated from the staining intensity and the percentage of positive
cells according to a board-certified pathologist opinion [29].
Real-Time PCR
Quantitative determination of MMP-1 mRNA was carried out as
described [21]. cDNA was subjected to quantitative real-time PCR
analysis using an iCycler Instrument (Bio-Rad, Hercules, CA).
Luciferase Reporter Gene Assay
Exponentially growing cells of A549 (7 × 105) were plated into
six-well cluster plates (Greiner) in 2 ml of RPMI 1640/10% FCS and
grown to 80% to 90% confluency. The cells were washed, transferred
into 1 ml/well fresh medium, and cotransfected with 1 μg of MMP-1
promoter/luciferase constructs and 0.1 μg of the pRL-TK Renilla
luciferase plasmid (Promega, Madison, WI) through Polyfect (Qiagen,
Hilden, Germany) and optionally stimulated with IL-6 (20 ng/ml) for 8
hours. Luciferase and Renilla activities were determined using a Micro
Luminat LB 96 P luminometer and reported as relative light units.
Statistics
Significance of immunohistochemical data was evaluated using
the Wilcoxon rank-sum test, and data correlation was examined
with the tau-b-test according to Kendall employing the SPSS
11.2 software package for data calculation. Luciferase reporter
gene results were evaluated by unpaired t test using GraphPad
Prism software.
Results
STAT3 is Persistently Activated and MMP-1 Is Co-Expressed
in Lung Cancer Biopsies
Twenty-four NSCLC biopsies were obtained in the course of
tumor resections. The patients were staged according to operation
and pathologic findings after UICC (Union Internationale Contre le
Cancer) criteria. With respect to TNM (Tumor, Node, Metastasis)
classification, 8 patients were categorized in stage T1, 11 in stage T2,
and 2 in stage T4. Regarding the differentiation grade, one tumor was
classified as G1, 14 were classified as G2, and 6 were classified as G3.
Details on the tumor specimens are summarized in Table 1.
The surgical specimens were investigated for both pYSTAT3 and
STAT3 as well as for MMP-1 expression by Western blot analysis.
Figure 1 shows the results for a representative selection of tumor
tissue samples. Table 1 gives staining scores for the whole panel of
biopsies covered by this study. In total, 19 of 24 examined biopsies
(79%) displayed constitutive pYSTAT3, although to different
degrees. All samples were positive for the active form of MMP-1.
STAT3 Activation Coincides With Expression of MMP-1 in
Lung Cancer Tissue
We next performed an immunohistologic examination of tumor
biopsies with antibodies to pYSTAT3 andMMP-1. Two representative
examples for specific staining of consecutively sectioned biopsies are
presented in Figure 2A. In the vast majority of cases, pYSTAT3 activity
was present in tumor regions that were also positive for MMP-1.To assess this relation more thoroughly, we analyzed the complete
available collection of roughly 100 lung cancer biopsies for both
pYSTAT3 andMMP-1. Staining intensities were determined for tumor
center and invasive front areas and expressed using the scores 0, 1, 2, and
3 as described in the Materials and Methods section. AC samples (N =
43) and SCC samples (N = 53) were evaluated separately. As shown in
Figure 2B, activity levels of STAT3 (appearance of pYSTAT3) and
expression levels of MMP-1 were significantly higher in the invasive
fronts of bothACs and SCC compared to the tumor centers (P b .001 in
all cases). Interestingly, using Kendall's tau correlation, a significant
association was found for pYSTAT3 andMMP-1 in both invasive front
and central areas of ACs (Kendall-tau-b 0.346/P = .008 and 0.270/P =
.046, respectively). In SCC, such a tendency was also seen, although
statistical significance was not reached.
This observation prompted us to study spatial coincidence of pYSTAT3
andMMP-1 by double immunofluorescencemicroscopy. Figure 2C shows
a typical example of pYSTAT3 andMMP-1 signals co-localizing in tumor
tissue with phosphorylated, activated STAT3 accumulated in nuclei and
MMP-1 expression appearing mostly perinuclearly and extracellularly, in
line with the role of MMPs in modifying the extracellular matrix.
STAT3 is Constitutively Active in Lung Cancer Cell Lines
Next, we analyzed the status of pYSTAT3 in nine established lung
cancer cell lines. As shown in Figure 3, all cell lines tested showed
constitutive STAT3 activation with a wide range of activity spectra,
Figure 2. Correlation of STAT3 activation and MMP-1 expression in NSCLC biopsies. (A) Immunohistochemical analysis of
tyrosine-phosphorylated STAT3 (left) and MMP-1 expression (right) in tumor tissue of an arbitrarily selected SCC from the patient
cohort studied in this manuscript. Paraffin-embedded sections were stained with an antibody to tyrosine-phosphorylated STAT3 or
MMP-1, respectively, as indicated, followed by microscopic visualization employing goat anti-goat or anti-mouse biotin, respectively, and
streptavidin-HRP. Scale bars represent 50 μm. (B) pYSTAT3 (left) andMMP-1 (right) abundance in NSLCC biopsies. Immunohistochemical
staining intensities in AC (N= 43, top part) and SCC (N= 53, bottom part) samples were determined for tumor center (Cen.) and invasive
front (Inv.) areas as indicated and expressed by box plots using the scores 0, 1, 2, and 3 as described in the Materials and Methods
section. Significance of mean differences in staining intensities between invasive front and tumor center areas (P b .001) is indicated by
asterisks. Τ and P values determined by Kendall's tau correlation for the mutual association of pYSTAT3 and MMP-1 in both tumor types
are indicated. (C) Immunofluorescence photomicrographs of a representative SCC section immunoreactive for anti-pTyr705 STAT3 (left,
green fluorescent due to staining with Cy2-labeled goat anti-rabbit secondary antibody) and anti-MMP-1 (center, red fluorescent due to
staining with Cy3-labeled goat anti-mouse secondary antibody). Right: Overlay of green and red fluorescence indicating co-localization of
antigens. Images were taken using a Zeiss LSM 510 Meta confocal microscope device; scale bars represent 10 μm.
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ing tyrosine kinase mutational context. The expression levels of
STAT3 were comparable, but the intensity of phosphorylation ranged
from barely detectable (NCI-H69) to very strong (NCI-H82). In all
cell lines, at least two different STAT3 splice variants appeared in
tyrosine-phosphorylated form, most probably STAT3 α and β. These
results show that permanent cell lines derived from lung cancer tissue
preserve autonomous STAT3 activation independently from a
specific in vivo environment, which is quite different to colorectal
cancer cell lines as we have published [9,21].
IL-6–Induced STAT3 Activation in Lung Cancer Cell Lines
Causes Elevated MMP-1 Expression
Previously, we have shown that in colon carcinoma cell lines
STAT3 activation can be induced by IL-6 stimulation [9]. We
analyzed lung cancer cell lines for their responsiveness to IL-6 by
assaying pYSTAT3 (Figure 4A). Three of the cell lines employed in
this study (BEN, KNS62, A549) showed a clear and specific increase
in pYSTAT3 in dependence of IL-6. Having established a means to
experimentally induce STAT3 activation, we addressed a possibleFigure 3. Analysis of STAT3 expression and activity in lung cancer
cell lines. Samples of the indicated cell lines were lysed, separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis,
and subjected to Western blot analysis onto nitrocellulose
mebranes. Membranes were subsequently probed with an
antibody specifically recognizing STAT3 phosphorylated at tyrosine
705 (top). Comparable loading of the lanes and identity of STAT3
were confirmed by reprobing with an antibody to STAT3 (bottom).
Arrows point to STAT3 isoforms STAT3 α and STAT3 β.causal link between STAT3 activity and expression of MMP-1 in lung
carcinoma cells, and mmp-1 gene transcription was assayed by
real-time PCR upon activation of STAT3 by IL-6 in the three lung
cancer cell lines BEN, KNS62, and A549. Figure 4B shows that
incubation of all three cell lines with IL-6 leads to a clear increase in
mmp-1 mRNA. Relative induction factors were 2.7 for BEN, 2.8 for
KNS62, and 42.8 for A549. These results suggest that STAT3 is
directly involved in the control of mmp-1 expression in lung cancer.
STAT3 Transcriptionally Activates the MMP-1 Promoter in
A549 Cells
To show that STAT3 is directly operative in regulating expression of
theMMP-1 gene in lung cancer cells, we generated a pair of A549 cells
in which STAT3 expression was either present or abolished by a
knockdown approach. STAT3 expression in A549 cells was knocked
down by lentivirus-mediated introduction of a STAT3-specific shRNA.
For control purposes, a parallel experiment was performed using a
scrambled (scr) sh sequence. Specific k.o. of STAT3 expression in the
shSTAT3 cell line was confirmed by Western blot (Figure 5A).
We have previously used a reporter gene construct (−4372-hMMP-luci)
containing a 4.3-kb promoter fragment of the MMP-1 gene to study
transcriptional activation [21]. This DNA was transfected into the two
A549 cell derivatives described above to study the role of STAT3 in
MMP-1 promoter regulation. Figure 5, B and C, shows that IL-6
stimulation evokes reporter gene activity in A549 cells that express
STAT3 (“sh scr”), whereas in the STAT3 k.o. A549 line (“sh STAT3”)
this responsiveness is heavily impaired. From these findings, we deduce
that STAT3 is of prime importance for transcriptional regulation of the
MMP-1 cell in lung cancer cells.
Next,we analyzed the contribution of STAT3 to the control ofMMP-1
promoter function in A549 cells in somemore detail. For this purpose, we
employed reporter gene construct pMMP-1-0.6 k, in which a 600-bp
fragment of the MMP-1 promoter was placed upstream of a luciferase
reporter gene [30].Within a DNA segment between 100 and 150 bp
upstream of the transcriptional start site, the human MMP-1 promoter
contains both a STAT and an AP-1 recognition element [STAT binding
element (SBE) and AP-1 binding element (AP1BE); Figure 5D, “w.t.”].
Transient transfection of pMMP-1-0.6 k into A549 cells and
subsequent stimulation with IL-6 led to a significant increase in
reporter gene activity compared to non-stimulated cells (Figure 5E,
leftmost bar), indicating that STAT3 activation also promotes
transcriptional activity of the shortened MMP-1 promoter. A
Figure 4. IL-6–inducible tyrosine phosphorylation of STAT3 and concomitant transcriptional activation of theMMP-1 gene in lung cancer
cell lines. (A) Cell lines BEN, KNS62, and A549 were grown to 90% confluency in full medium, then starved from FCS for 6 hours, and
subsequently treated optionally for 30 minutes with 10% FCS or different concentrations of IL-6 as indicated. Cells were then lysed and
extracts were separated, blotted, and analyzed for STAT3 phosphorylation and expression as in Figure 3. (B) IL-6–dependent MMP-1
expression in A549 lung cancer carcinoma cells. Cells were grown for 24 hours in the absence or presence of 20 ng/ml IL-6 as indicated.
Total RNA was isolated, reverse transcribed into cDNA, and quantified by reverse transcription–PCR with specific MMP-1 primers and
probes. Signal intensities derived from respective non-stimulated cells were set to 1. Results from a typical experiment out of at least
three independent experiments are shown.
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AP-1 in transcriptional activity of the MMP-1 promoter in bladder
carcinoma cells [31]. To address the respective roles of both factors for
MMP-1 expression in lung cancer, we disrupted their binding sites
individually and in combination in the context of the 0.6-kb
promoter fragment to yield constructs mutated SBE, mutated
AP1BE, and mutated AP1BE/SBE (Figure 5D) and tested the
activation of the mutated constructs in response to IL-6 in A549 cells.
Notably, destruction of the STAT3 binding element clearly reduced
transcriptional activation by IL-6. A more pronounced effect,
however, resulted from the disruption of the AP1BE, which
eliminated activation almost completely, even if the core STAT3
cognate site was still intact (Figure 5E ). We deduce from these
findings that the STAT3 binding site at the −133 position relative to
the transcriptional start site of the MMP-1 promoter participates in
MMP-1 mRNA regulation but can only be engaged if simultaneous
AP-1 binding to the neighboring AP1BE occurs.
Discussion
Both STAT3 and MMP-1 have been implicated in lung cancer. The
regulation of MMP protease activity in SCLC cells was so far not
linked to JAK-STAT or inflammatory cytokine signaling. However,
association of STAT3 activity and lung cancer progression is not
restricted to NSCLC and has also been described in SCLC [32].Various findings point to dysregulated STAT3 activity as a
determinant of a malignant cell behavior and as an interesting
therapeutical target in lung cancer: It has, for instance, been shown
that blockade of STAT3 function by a dominant negative mutant in
human lung cancer cells leads to suppression of oncogenic growth
[11]. The cytokine signaling suppressor SOCS-3 can reduce
STAT3-driven cell proliferation in a physiological context and is
frequently found silenced by hypermethylation in human lung cancer
cells [33]. More recently, it has been demonstrated that oral
administration of a bioavailable small molecule STAT3 inhibitor
could interfere with the development of xenograft tumors derived
from lung cancer cells [34]. STAT3 activity is not only relevant for
tumor growth but also influences invasiveness in NSCLC as suggested
by a recent kinome profiling approach [35].
Interestingly, STAT3 hyperactivation in lung cancer does not
exclusively originate from cytokine receptor signaling, but it was also
shown to be connected to EGFR or ErbB2 hyperactivity. The ErbB2
kinase is required for constitutive STAT3 activation in malignant
human lung epithelial cells [36]. It has also been observed in other
cancer types that IL-6–dependent activation of STAT3 does not
necessarily require JAK activity and can be blocked by inhibitors of
the Mitogen-Activated Protein Kinase (MAPK) pathway [37]. IL-6 or
IL-11 signaling were recently shown to originate from the tumor
stroma as a cytokine source [6]. Particularly, cancer-associated
Figure 5. Influence of STAT3 activation in lung cancer cell line A549 cells on wild-type and mutant MMP-1 promoter activities. (A)
shRNA-mediated knockdown of STAT3 expression in A549 lung cancer cells. Comparative analysis of STAT3 expression in A549 stably
expressing in a STAT3-specific shRNA sequence or a scrambled control shRNA sequence by Western blot and probing with an antibody
to STAT3 was performed. The blot was reprobed with an antibody to HSC-70 to verify equal loading. (B) Effect of STAT3 knockdown on
IL-6–dependent activation of the MMP-1 promoter. Luciferase reporter gene construct −4372-hMMP-luci containing a 4.3-kb promoter
fragment of the human MMP-1 gene was transfected into STAT3 k.o. A549 cells (shSTAT3) and into control cells (sh scr) along with a
Renilla luciferase reporter gene construct for normalization purposes as detailed in the Materials and Methods section. Fourteen hours
post-transfection, cell samples were split and incubated for further 8 hours in the absence or presence of 20 ng/ml human IL-6 as
indicated. Luciferase activities were determined, normalized against Renilla luciferase activity, and expressed as arbitrary luciferase units
(AU). Data represent the means of three independent transfections, each run in triplicate. Error bars show SDs; an asterisk indicates
statistical significance (P b .05). (C) Relative representation of data from B. Stimulation indices are expressed as the ratios of specific
luciferase activities of IL-6–stimulated and unstimulated cells; basal luciferase measured in unstimulated cells was set to 1. (D) Sequence
context of original (“w.t.”) and single or combinatorially mutated (“mt”) SBE and AP1BE in reporter gene constructs based on a 0.6-kb
proximal region of the human MMP-1 promoter (pMMP-1-0.6 k). Wild-type and mutant core binding elements are boxed in the respective
constructs; numbers indicate nucleotide positions relative to the transcriptional start site of the MMP-1 promoter. Mutated nucleotides
appear underlined and in bold italic. (E) IL-6–dependent transcriptional activity of the indicated wild-type and mutant versions of
pMMP-1-0.6 k–derived reporter gene constructs. Reporter gene assays were performed as in B; data are presented as in C.
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triggered by transforming growth factor–β signaling from carcinoma
cells. Similarly, IL-6 trans-signaling is triggered by myeloid immune cell
infiltration [39]. Altogeher, these findings and our results suggest that in
particular targeting andblocking STAT3activation is relevant for interference
of lung cancer invasion downstream of either hyperactive tyrosine
kinase or inflammatory cytokine stimuli to ablate MMP-1 expression.
Notably, cooperativity of STAT3- and AP-1–mediated transcrip-
tional regulation of the human MMP-1 promoter has also been shown
in colon and bladder cancer cells [30,31]. Moreover, we have analyzed a
small collection of colorectal cancer biopsies for STAT3 and AP-1 and
observed combined aberrant activities of both factors in the majority of
cases [31]. In the light of the present study, it will be important to
determine if a significant correlation exists in lung cancer.Several reports point to an involvement of STAT3 in the
development of resistance to chemotherapy and radiotherapy [40–42].
Targeting STAT3, thus, has the potential of improving treatment
efficacy in lung cancer [43]. The role of STAT3 activation in lung cancer
is probably related to inflammatory processes. Interestingly,
chitinase 3-like 1, the product of a STAT3 downstream target gene,
is a biomarker of inflammation-induced lung cancer [44].
Elevated MMP-1 expression was associated with unfavorable
outcome and progressed lung cancer cases. MMP-1 levels were found
increased in tumor samples compared with matched, corresponding
normal tissues. Strong MMP-1 expression was correlated significantly
with the occurrence of tumor–lymph node metastasis [23]. Moreover,
in patients with lymph node metastasis, MMP-1 overexpression was a
negative prognostic factor and associated with shorter survival [40].
104 MMP-1 and STAT3 in Lung Cancer Schütz et al. Translational Oncology Vol. 8, No. 2, 2015We showed that transcriptional activity of the MMP-1 promoter is
modulated through concerted interaction of STAT3 and AP-1 factors
with specific recognition elements [26]. It will, thus, be interesting to
address whether aberrant EGFR function may contribute to
malignancy in lung cancer through parallel activation of both MAP
kinase and JAK/STAT signal transduction pathways.
Taken together, our findings suggest that the combined activities of
both STAT3 andMMP-1 should be considered asmolecular parameters
of NSCLC and, along with EGFR and Src activity, should be further
evaluated as potential targets for individualized tumor treatment.
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